We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App




Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions

By LabMedica International staff writers
Posted on 07 Feb 2024
Print article
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)
Image: The DI-60 automated digital cell morphology analyzer developed by Sysmex in collaboration with CellaVision (Photo courtesy of Sysmex)

Sysmex Corporation (Kobe, Japan) has entered into a strategic alliance agreement with CellaVision (Lund, Sweden) to advance hematology solutions. This collaboration aims to expand Sysmex's product range, including the development of cutting-edge cell morphology analyzers. Together, Sysmex and CellaVision will strive to improve the efficiency and standardization of testing workflows in hematology, enhance the accuracy of cell morphology classification, and provide valuable support in diagnostic processes.

The partnership between Sysmex and CellaVision has spanned 20 years, focusing on hematology, which involves the analysis of blood cells such as red and white blood cells in terms of their count, types, and sizes. This collaboration began in 2001 when Sysmex entered a sales alliance for CellaVision’s cell morphology analyzers. In 2013, Sysmex introduced the DI-60 Automated Digital Cell Morphology Analyzer, a product of its collaboration with CellaVision. This system, when integrated with Sysmex’s hematology analyzers, automates up to the cell morphology analysis stage, significantly streamlining and standardizing testing workflows in clinical laboratories worldwide.

The renewed partnership between the two companies aims to enhance their product offerings, particularly in next-generation cell morphology analyzers. They have agreed to extend their collaborative efforts to advance hematology solutions and maintain their agreement until 2038. Leveraging a stable, long-term collaborative framework, Sysmex plans to utilize its expertise in optimizing testing workflows in hematology, while CellaVision will contribute its advanced digital imaging and analysis technologies. These joint efforts are intended to further improve efficiency and standardization in testing workflows and increase clinical value by providing more precise cell morphology classification to aid in diagnoses.

“We are pleased to expand our alliance with CellaVision since 2013,” said Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation. “This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”

"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey,” said Simon Østergaard, President & CEO, CellaVision AB. “We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”

Related Links:
Sysmex Corporation
CellaVision 

Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
hCG+β Automated Immunofluorescent Assay
B·R·A·H·M·S hCG+β KRYPTOR
New
Neuron-Specific Enolase ELISA
Human NSE ELISA Test Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The researchers used state-of the-art equipment for isotope ratio mass spectrometry (Photo courtesy of The University of Melbourne)

New Blood Test to Detect Alzheimer’s Disease Before Clinical Symptoms Develop

Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60-70% of cases worldwide, totaling over 33 million, according to the World Health Organization. As the global population ages,... Read more

Hematology

view channel
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: The ChatGPT-like AI model can diagnose cancer, guide treatment choice, predict survival across multiple cancer types (Photo courtesy of 123RF)

AI Tool Diagnoses Cancer, Guides Treatment and Predicts Survival Across Multiple Cancer Types

Current artificial intelligence (AI) models are typically specialized, designed for specific tasks like detecting cancer or predicting tumor genetics, and are limited to a few cancer types.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.